






SOCIETAL DRUG USE 
A CRITICAL REVIEW 
 






A thesis submitted in the fulfilment of the 
requirements for the degree of 
 










Dr John Coumbaros 
 














I declare that this thesis does not contain any material submitted previously for the award of any other 
degree or diploma at any university or other tertiary institution. Furthermore, to the best of my 
knowledge, it does not contain any material previously published or written by another individual, 
except where due reference has been made in the text. Finally, I declare that all reported 
experimentations performed in this research were carried out by myself, except that any contribution 























I would like to express my gratitude to my supervisor, Dr. John Coumbaros, for his professional 
guidance, patience and knowledge throughout the learning process of this thesis.  
Furthermore, I would also like to acknowledge Cahill Hunt, Elizabeth Morahan and Phi-Lam Vu for 
supporting me and giving me the confidence and guidance to get me through this degree, without 




Table of Contents 
Title Page 
Declaration ........................................................................................................................................ i 





























Wastewater-based Drug Epidemiology to 





Illicit drug use has many consequences resulting in social, health, and economic harm. An 
objective method of quantifying societal drug use would be useful for the efficient directing 
of the efforts of law enforcement, medical facilities and policy makers, and to inform the 
community. To this end, efforts to ascertain societal drug use have relied upon community 
surveys and extrapolation from law enforcement seizures, which often present the data as 
biased or skewed due to a small sample size and other associated limitations. 
 
In recent times, wastewater-based drug epidemiology (WBDE) has been proposed as a 
suitable means to objectively quantify societal drug use. WBDE is the study of the incidence 
and distribution of drug use within a population and the its factors affecting the health and 
welfare. It is a method contingent upon the concept of measuring drug metabolites or 
biomarkers in wastewater (WW), from which levels of societal drug use are estimated and 
quantified through extrapolation and back-calculations. 
 
The aim of this study was to critically review the various methods of WBDE that have been 
applied in Australia and in Europe. The outcomes of the assessment pertaining to their 
validity in directly and objectively measuring societal drug use will be presented. 
Keywords: wastewater-based drug epidemiology, wastewater-based epidemiology, illicit 
drugs, drug abuse, estimate, societal drug use, population 
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Illicit drug use has been long debated and plagued society, especially in the modern world 
with new drugs surfacing rapidly. While some argue the beneficial and medicinal effects of 
some drugs, particularly cannabis1,2, typically, illicit drug use has a negative effect on society, 
and is viewed as being responsible for immense social, medical, policing, and economic 
burdens. Illicit drug use in the community has been shown to affect the individual’s 
interaction and connection to society, often resulting in detrimental disconnection from the 
world around them. Drug use not only affects the user, but also their family and friends, 
extending out to the community around them. 
 
Illicit drug abuse has been shown to stabilise across the recent years, the National Drug 
Strategy Household Survey (NDSHS) of 2016 reported similar proportion of lifetime use as 
2013, 43% and 42% respectively. However, it was also noted that there has been a gradual 
increase since 2001, which reported 38% of the Australian population aged 14 or older had 
used illicit drugs at some point of their life3. Cocaine, synthetic cannabinoids and psychoactive 
substances all demonstrate an increase in proportion of lifetime use, namely from 8.1% to 
9.0%, from 1.3% to 2.8% and 0.4% to 1.0% respectively3. Approximately 15.6% of the 
Australian population aged 14 or older have reported illicit drug use within the last 12 months 
in 2016 and has been stable since 20043. There was no significant increase in any specific illicit 
drug use since 20133. In relation to the use of novel psychoactive substances (NPS), the NDSHS 
reported an increase of more than doubling, from 1.3% to 2.8%, of lifetime use of synthetic 
cannabinoids but a decrease in recent use from, 1.2% to 0.3%, from 2013 to 2016. Simply 
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meaning that there was an increase of experimentation among the population but a reduction 
in chronic use. 
 
The impact of illicit drug use on society can be classed into two types:  tangible and intangible 
costs4. Tangible costs are the quantifiable costs to society, which can be categorised as those 
resulting from (1) workplace labour, (2) labour in the household, (3) healthcare and (4) crime. 
Examples of the quantifiable costs as a consequence of illicit drug use from each category are 
briefly elaborated; (1) reduction in the workforce and absenteeism, (2) premature death and 
illnesses, (3) pharmaceuticals, hospital and medical costs, and (4) policing, courts and prison4. 
In 2004-05, these costs totalled to just over 6.9 billion dollars, combining the tangible costs 
from workplace labour, household, healthcare and crime4. This makes up 0.88 percent of the 
gross domestic product4. Intangible costs refer to unquantifiable costs from, for example, the 
loss of life or loss of productivity in a workplace as a consequence of illicit drug use The 
intangible cost attributed to loss of life and pain and suffering were almost 1.3 billion dollars4.  
 
Burden can be qualitatively expressed as years of lost life (YLL) or years left with disability 
(YLD)4-6. In 2018, the Australian Institute of Health and Welfare reported that illicit drug use 
was responsible for 2.3% of the total burden of disease and injury in Australia for 2011 and 
1.3% of deaths6. Years of life lost (YLL) as a result of illicit drug use was equivalent to 70,419, 
3.1% of all fatal burdens in Australia, and of the non-fatal burdens, illicit drug use was also 
responsible for 1.4% of the total, equivalent to 31,447 years lived with disability (YLD)6. It was 
also reported that lower socio-economic groups contribute the greatest burden as a result of 
drug use6. In 2004/05, the cost of crimes that could be attributed to illicit drugs was found to 
total almost 4 billion dollars, with 43% of costs contributed by the police sector alone4. In the 
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same period, net cost impact on healthcare resulting from illicit drug use was reported to 
total 201.7 million dollars4. The collective impact of illicit drug abuse on the state and federal 
budget in 2004/05 was reported to total to almost 2.4 billion dollars4. It is important to note 
that this sum does not include the budgetary impact of illicit drug use, but solely its abuse. 
Between 1998/99 and 2004/05, there has been an 11.3% increase in total cost of illicit drug 
use; at 2004/05 prices4. It is important to understand that the culture of illicit drug use has 
drastically changed, with the decline in the prevalence of some illicit drug use and the 
emergence of new drugs such as NPSs.  
 
NPS are synthetic substances that are made to mimic the effects of existing psychoactive 
drugs such as cannabis, ecstasy (MDMA), heroin and cocaine5,7. The European Drug 
Monitoring Centre for Drugs and Drug Addiction reports that since 2010, there has been a 
significant increase in the first detection of new NPS, with 70% of all being detected in the last 
5 years alone7. The production of these NPSs occurs at a faster rate than the ability to assess 
the possible detrimental effects of the drug. How this occurs, is that production of substances 
that mimic already existing substances do not require a lot of work. It involves minor changes 
in the chemical structure of the substance that allow it to be undetectable to current 
screening methods for the existing substances. It is for this reason that most NPSs avoid 
legislation and appear.   
 
In the past, the methods of measuring societal drug use were dependent on community and 
government surveys3,8-12. Surveys are often open to self-report bias, as they are reliant on an 
individual’s recollection of events. This problem could be compounded when examining the 
prevalence of illicit drug use, as the physiological and psychological effects of drugs could 
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further impact recollection. For example, the effects of cannabis use include polyphagia, 
colloquially known as “the munchies”, euphoria, and impaired short term memory13,14; or the 
use of cocaine elicits paranoia, mydriasis and extreme elation and energy15-17. It is recognised 
in law that the actions and memory of an individual while under the influence would often 
result in the discreditation of their statement in court18. To this effect, then, the reliability of 
the individual to recollect the events of drug use becomes, furthermore, unreliable.  
 
The standard method of collecting community data is through conducting surveys. Often in 
paper form, they can also be conducted via the phone or electronically. The cost of 
distributing and conducting surveys, and then additionally analysing them thereafter is 
costly19. A study assessed the voluntary participation in a weekly survey regarding illicit drug 
use; found that within a population of 29,083, only 1% of individuals completed the surveys20. 
In addition to conducting surveys, data on drug use can be gathered from police, medical 
reports and workplace drug testing. The National Drug Strategy Household Survey is an 
Australian based voluntary questionnaire that has been conducted every 2-3 years since 1985, 
collecting information on the use and perception of alcohol, tobacco, illicit drug and 
pharmaceuticals3,8-12. The most recent NDSHS conducted in 2016 is the first in the series to 
introduce the option of completing the form online3. In this instance, the mode in which the 
survey was conducted may have had an impact on the responses given. For example, the 
persons completing the survey may have responded in the way they think the interviewer 
wants them to respond or may deter from revealing information in some cases where the 
action is illegal. The 2016 NDSHS did establish an increase in response rate from 49.1% and 
50.6% in 2013 and 2010 respectively to 51.5%. This increase could possibly be attributed to 
the introduction and ease of completion of the online form option, creating incentive to 
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continue online forms. However, the increase is slight and may have been attributed to other 
unrelated factors3.  
 
In order to accurately portray the level of societal drug use, data must be presented in an 
unbiased and objective manner. Wastewater-based drug epidemiology (WBDE) has been 
proposed as a method that can objectively and directly measure societal drug use21. 
Wastewater-based epidemiology (WBE) is the analysis of wastewater (WW) to understand 
the incidence and distribution of various factors relating to health. WBDE to estimate societal 
drug use is essentially the analysis of WW to detect drug analytes, which are then utilised to 
evaluate real-time societal drug use based on the population the WWTP serves20-39. The 
concept was first proposed by Daughton et al. with the aim to assess the effect of drug 
excretion products on the environment, specifically aquatic life21. Since then, the theory has 
been broadened to assess the extent of societal drug use. A study conducted by Jones-Lepp 
et al. was the first to demonstrate a method to detect and confirm the presence of illicit drugs 
in effluent WW40. Zuccato et al. laid out the first initial studies contributing to WBDE to 
estimate societal drug use and assessed cocaine use in Italy by back-calculating using the four 
factors, drug concentration detected, water flow rate, excretion rate of the drug target 
residue (DTR) and the number of people served by the WWTP27. Since then, many studies 
have adapted this method to optimise it from a robust method to a method that can deliver 
with greater accuracy the knowledge of societal drug use. Wastewater-based drug 
epidemiology studies are still in their infancy and demonstrates great potential in their ability 
to estimate societal drug use. WBDE has the potential to track and relay near real-time 
community drug use and portray patterns of use throughout a time course: over the course 
of the week, year or public holidays20-26,29,31-33,37-39,41-49; or during the time leading  towards a 
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large public event50, as well as the pattern of use between drugs. It can identify hotspots of 
drug use to assist policy makers and law enforcement to better target their efforts. An added 
advantage WBDE has over other methods of data collection on drug use in a community, such 
as those gathered from surveys, police and medical reports, is that the methods of WBDE are 
non-invasive and retains the anonymity of drug users. The data collected from these studies 
have no way of being traced back to any singular individual and therefore will not implicate 
them in any illegal activity of illicit drug use. The aim of WBDE is not to incriminate individuals 
but to provide accurate near real-time information on illicit drug use in the community to the 
relevant parties. For these reasons, the methods of WBDE require validation so that they may 
successfully and efficiently be utilised. This critical review aims to assess the validity of the 
currently available methods, in their ability to objectively and directly evaluate drug levels in 
WW to estimate societal drug use. 
 
5.1 THE PURPOSE OF MEASURING SOCIETAL DRUG USE 
The understanding of true societal drug use is highly important. With the ability to accurately 
assess real-time societal drug use, the efforts of various community groups such as law 
enforcement, medical professionals and the government bodies and policy agencies, can be 
better directed and budgeted. Drug use has a large impact on every facet that makes up a 
community. Millions of individuals have reported to be current users of illicit drugs such as 
cocaine, heroin, amphetamine and methamphetamine3. The consequences of the use of 
these drugs produces a negative ripple effect to the rest of the community. From eliciting 
significant negative consequences on individual health, to diminishing social behaviour, 
extending its impact to family and friends, and then to the rest of the community. The impact 
of illicit drug use is devasting, with some individuals developing substance abuse disorder, 
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addiction3,51. Estimates on societal drug use could help highlight and raise awareness to the 
drug epidemic. And by understanding the different levels of various illicit drug use in society, 
allowing the best strategies to be formed to combat them.  
 
Addiction is a devastating consequence of drug use. In 2015-16, the number of treatment 
episodes conducted for alcohol and drug treatment had a 40% increase from 140,475 to 
198,747 episodes, with treatment for drug use accounting for the majority over the past 10 
years52. Drug clinics and rehabilitation centres offer different detoxification and treatment 
programs depending on the illicit drug that has caused the addiction. No one medication 
program assists with all drug addictions. Each program requires various concoctions, various 
doses and dosing schedule and plans53. By understanding the level of drug use in society, this 
may allow drug clinics and rehabilitation centres effectively organise, budget and regulate the 
pharmaceuticals required for each program.  
 
Though drug use may have gradually decreased throughout the years, there has been an 
emergence of more potent, dangerous drugs41. New psychoactive synthetic drugs are an 
emerging group of drugs coming into circulation. As technology advances, new synthetic 
drugs42,54 come into play requiring better screening techniques to adequately evaluate its 
contribution to drug use in the community. Generally, the basic screening methods only 
search for chemicals that have specifically been targeted. Newer screening methods would 




With better developed and refined techniques, WBDE could potentially identify trends in drug 
use that can then be used to devise programs or campaigns to best combat the use of 
dangerous illicit drugs that harm the community.  
 
6. DRUG PHARMACOLOGY 
Drugs can be described as substances that produce a physiological or biochemical effect on 
the body55,56. Each drug has a different potency, which requires different doses in order to 
elicit the same level of effect to another drug as well as dictate the route of administration to 
obtain optimum effects of the drug55. This is also affected by the individual’s age, ethnicity, 
genetic dispositions, weight and the presence of other diseases and the concurrent use of 
other drugs57. Though drugs will produce characteristic symptoms and effects, it is also 
important to note that each individual may exhibit slightly different reactions to a certain drug 
compared to another individual57.  
Pharmacology is the study concerned with the nature, effects and mode of action of drugs on 
our body57. Underpinning the study of pharmacology are the two broadly characterised 
phases of a drug’s effect: pharmacodynamics and pharmacokinetics. Pharmacodynamics 
describes the effect a substance will have on the body, whereas pharmacokinetics describes 
the body’s actions onto the drug55,58. Understanding the pharmacology of substances is 




Pharmacodynamics is the study of the magnitude of drug response on the body. Specifically, 
it refers to the binding of the drug to the drug target and the response produced from the 
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binding, the intensity and duration of drug response and its relation to drug 
concentration55,56. Drug response occurs once the drug binds to its corresponding receptor 
and produces a chemical reaction by altering the conformational arrangement of the 
receptor55,56,59. At high drug concentrations, more receptors are occupied resulting in a higher 
response than low drug concentrations where fewer receptors would be occupied55. The type 
of stimulus produced by the drug depends on the relationship between the drug and the 
receptor, whether the drug is an agonist, partial agonist or antagonist59. An agonist would 
mimic the response produced by the receptor-ligand when it binds to the receptor, whereas 
when an antagonist binds to its receptor, it would inhibit and block the response usually 
produced by the binding of a receptor ligand55,56,59. And a partial agonist would elicit a fraction 
of the response produced by a receptor ligand binding55,56. Drug efficacy and affinity with the 
respective receptor are factors that also influence the overall response produced by the 
drug55. Typically, the interaction between the receptor and the corresponding drug is 
reversible in nature and once drug response is completed, the drug dissociates from the 
receptor and drug response dissipates. The events that occur to the drug after this is referred 
to the pharmacokinetics of the drug56,60.  
 
6.2 PHARMACOKINETICS 
Pharmacokinetics describes the study of drug concentration in relation to time and 
movement in the body, from administration, distribution throughout the body and excretion 
from the body55,56,60. Therefore, it is the study of the absorption, distribution, metabolism and 
elimination (ADME) of the drug and how these aspects affect drug concentration in the 
body55,58. Drug concentration cannot be measured directly, instead plasma concentration is 
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measured instead56. Plasma concentration is assumed to reflect true drug concentration with 
often a linear relationship, however some drugs may exhibit greater, complex relationships55.   
 
6.2.1 ABSORPTION  
Common routes of administration include oral, topical, intravenous and intraperitoneal 
injections as well as nasal delivery, especially in regards to the intake of illicit drugs29,55,58. 
Absorption refers to the uptake of the drug into systemic circulation and is dependent on its 
various properties, dictating the drug’s ability to be readily absorbed through 
membranes55,56,58,60. Drugs usually pass through membranes by means of passive diffusion, 
however some uptake transporters may assist in facilitating the movement58. Route of 
administration affects the rate in which the drug is absorbed into the systemic circulation. For 
example, an oral administration would take more time than an intravenous administration as 
the drug must travel to the gastrointestinal tract before dissolving, and passing the membrane 
before entering the systemic circulation, whereas the latter would deliver the drug directly 
into the systemic circulation55. Circumstances may also dictate the route of administration, 
whether the individual requires or desires immediate and maximum effect of the drug. The 
form in which the drug comes also impacts the rate it enters the systemic circulation as well 
as the magnitude of the response59,61. Common forms include tablet, capsule, powder, syrups, 
in a solution or pure liquid form. In conjunction with these aspects, the chemical properties 
of the drug, whether it is lipid soluble, aqueous soluble, polar or non-polar in nature, 
collectively impacts the rate and ability of drug absorption into the systemic circulation and 




2.2.1.1 BIOAVAILABILITY  
Bioavailability of the drug is a common aspect in understanding the pharmacokinetics of the 
drug as it describes the fraction of the dose that successfully enters the systemic 
circulation55,56,58,61. It can be further divided into three categories; fraction absorbed, 
intestinal bioavailability and hepatic bioavailability56. Portions of the drug can be lost at each 
of these points, and so collectively these factors together will describe overall bioavailability 
of the drug56.  
 
6.2.2 DISTRIBUTION  
The process of distribution of the drug within the body is concerned with its ability to access 
its site of action with the target receptors and the relative distribution between plasma and 
the rest of the body55,58. The rate and extent at which the drug distributes within the body is 
important to evaluate plasma drug concentration since direct tissue concentration cannot be 
reasonably measured56. The extent to which a drug has distributed to plasma relative to 
tissues assists in the understanding of the drug availability for the magnitude of drug 
response. Extensive distribution to the plasma compared to tissue would mean a lower 
magnitude of response as a large fraction of the drug is delivered to certain organs for 
elimination. Conversely, extensive distribution to tissues would enhance drug response but 
impede elimination, possibly leading to toxicity due to excess accumulation of the drug in the 
body56. Distribution is driven primarily by passive diffusion based on the concentration 
gradient of the unbound drug55,56. The drug may bind to plasma proteins or tissue 
macromolecules, which cannot participate in the concentration gradient56. This impacts the 
diffusion of the unbound drug. At equilibrium, the concentration gradient for the unbound 
drug is no longer a driving mechanism for diffusion, however a drug that extensively 
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distributes in plasma and binds to plasma proteins will contribute to a greater overall 
concentration of the drug in plasma55,56. The binding of the drug to plasma proteins or tissue 
macromolecules is an important factor in understanding the distribution pattern of the drug, 
dictating the areas in which the drug has access to55,56,58.  
 
6.2.3 METABOLISM  
Drug metabolism is the conversion of the parent drug to metabolites preparing it for removal 
from the body55,56,58,61. In some cases, the metabolism of the parent drug releases the active 
metabolite. These drugs are termed ‘pro-drugs’ and are chemically manufactured that way to 
ensure that the drug is not metabolised too rapidly before it is able to elicit its response58. 
The metabolite is then eliminated via the renal or biliary route55,58. The metabolic processes 
of metabolism in the liver are categorised as either a phase I or phase II process56. Phase I 
involves small modifications to the parent drug such as the removal of a methyl group or the 
addition of a hydroxyl group, both oxidation and reduction reactions may occur. Phase II 
processes describe the conjugation of the parent drug or the resultant phase I metabolite 
with a polar molecule via UDP-glucuronosyltransferase (UGTs) enzymes55,56,58,59. The liver 
houses the largest number and variety of drug-metabolising enzymes. The most important 
family of enzymes are the cytochrome P450 enzymes which are responsible for approximately 
75% of drug metabolism processes58.  
 
6.2.4 ELIMINATION  
The rate at which the drug undergoes metabolism and elimination is described by the 
elimination rate constant and half-life of the drug56. Factors that affect this are the 
determined by two factors, clearance and volume of distribution55,56,58,61. Clearance is a 
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constant that describes the ability of the elimination organs to efficiently extract the parent 
drug from the systemic circulation and eliminate it from the body61. It is essentially the 
proportionality between the rate of elimination and the present drug concentration in the 
plasma61. Volume of distribution describes the relative drug concentrations diffused between 
the plasma and tissue55,58,61. In order for the liver and/or kidney to have the opportunity to 
metabolise the parent drug and remove it from the body, it must have access to it by being 
present in plasma56. It is important to note that these primary parameters are independent 
of each other, and changes to either one does not affect the other parameter56. Total body 
clearance is additive of renal, hepatic and any other form of clearances56. 
 
6.3 PHARMACOEPIDEMIOLOGY 
Pharmacoepidemiology is the study of the distribution of drug effect within a population. 
Hennessy discusses the pharmacological aspects that contribute to pharmacoepidemiology 
studies55,57. Genetic polymorphisms are an example of population variation to 
pharmacodynamics of drug effect55,57. Age, diseased states, adapted drug responses and 
drug-drug interactions are other factors discussed by Hennessy that impact the 
pharmacodynamic drug response57. In addition, there are pharmacokinetic factors that are 
also considered in pharmacoepidemiology studies. Pharmacokinetic factors such as 
absorption, distribution, metabolism and elimination of the drug are also affected by genetic 
variabilities, age, diseased adaptive drug responses and drug-drug interaction57. Metabolism 
of drugs can either inactivate the parent drug or convert an inactive pro-drug to its active 
counterpart which will produce a therapeutic effect58. This process is assisted by the action 
of enzymes. Enzymes are proteins that are encoded for in DNA. For example, cytochrome 
P450 (CYP P450) is a major enzyme class that is responsible for almost 80% of all drug 
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metabolism processes in the body62-64. The genetic coding of these enzymes has been found 
to exhibit variations between individuals within population, as well as between ethnicities 
that are present within a population62-65. Extensive studies have been dedicated to the genetic 
variations that occur within the population with the expression of the CYP P450 enzymes62-
64,66,67. A characteristic that has been able to be determined from these studies is the 
categorisation of certain CYP P450 enzyme generating the phenotypes; ultra-metabolisers 
(UM), extensive metabolisers (EM), intermediate metabolisers (IM) and poor metabolisers 
(PM)66 of the corresponding drugs metabolised by the specific CYP P450 enzyme. Therefore, 
the rate and extent a drug is metabolised will also influence the level of excretion from the 
body. As demonstrated, the understanding of pharmacoepidemiology of the population in 
question can contribute to WBDE to aid in obtaining accurate societal drug estimates tailored 
for that population.  
  
7. DRUG ABUSE 
Illicit drug use has become an epidemic throughout many societies, casting burdens on the 
healthcare, society, law enforcement and the government. The total burden from illicit drug 
use has been reported to have increased by 6.9% from 2003 to 2011 in the latest report from 
Australian Institute of Health and Welfare on the impact that alcohol, tobacco and illicit drugs 
on the burden of disease6. They also report that illicit drug dependence was 5.6% higher in 
2011 compared to 2003. Many government reports and scientific studies directed towards 
illicit drug use have found that cocaine, methamphetamine, amphetamine, ecstasy, heroin 
and marijuana, to name a few, are typically the drugs with high abuse rates68-71. An emerging 
class of drugs of abuse are the NPSs, which are designed and created to mimic the 
physiological and psychological effects of existing psychoactive drugs5,7,41. These are 
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particularly significant, as many are not covered under current legislation, making them 
technically ‘legal’ for use. The use of these illicit drugs bring about a sense of euphoria, 
relaxation and a sense of escape from their everyday lives, which makes drug use appealing 
to these individuals13,59. Side effects of a drug is defined as any undesirable physiological or 
psychological implications, and the risk of side effects accompany any type of drug use. These 
may include paranoia, irritability, explosive violent behaviour and indifference to 
pain13,17,58,61. A genuine risk that accompanies continuous drug abuse is the possibility of 
becoming addicted to the substance. Drug addiction is defined as the chronic disease that is 
characterised by compulsive actions to seek out the drug and obtain it by any means72. It is 
defined as a disease due to the changes that occur to the brain chemistry and structure that 
occur due to the repeated drug abuse73,74. 
 
8. WASTEWATER TREATMENT PLANT 
Wastewater encompasses all the water that has been altered by human use, either within a 
household, corporation, or commercial setting75,76. This includes used water from toilets, 
sinks, manufacturing processes, shops and stormwater76,77. WW is collected and pooled 
within sewage pipes and transported to WWTPs where it undergoes a series of treatments to 
remove waste so that the water may be released back to the environment75-77. Initially, the 
primary treatment involves the removal of solid materials, including plastics and smaller 
particles such as sand77. The resultant WW then flows through large tanks where solids settle 
at the bottom of the tank and removed as sludge and oils and grease on the surface are 
skimmed77. Subsequently, secondary treatment utilises micro-organisms and aeration with 
oxygen to breakdown remaining wastes and fine particles and organic pollutants 
respectively77. WW sampling for experimental methods to estimate societal drug use can 
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either occur ahead of the treatments WW usually undergoes or subsequent to the 
treatments21. WW before treatment is termed influent water, and subsequent to the 
treatments is termed effluent water21.  
WW sample collection for WBE can either be collected as influent or effluent WW. Collection 
of influent water for samples mean that no treatment has been applied and methods would 
require a filtration and isolation of the drug metabolites from the contaminants21. Using 
effluent WW samples should be done with caution, as wastewater treatment processes could 
potentially remove some of the drug metabolites that are the target for WBDE21. 
WBDE is a relatively new area of research that can be utilised to estimate societal drug use. It 
involves the measurement of drug analytes, which can be in the form of drug metabolites, 
parent drug or drug biomarkers, in WW samples21,27. By incorporating the flow rate and the 
population number that the WWTP serves, a back-calculation can be performed to estimate 
the level of illicit drug use within the community that the WWTP serves27. WBDE hinges on 
the understanding that consumed illicit drugs are eventually excreted from the human body 
Figure 1. A typical wastewater tretment plant process67 
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in one form or another, often as a major metabolite in urine21. These drug analytes are the 
DTRs for WW analysis. 
 
9. WASTEWATER-BASED DRUG EPIDEMIOLOGY 
Wastewater-based epidemiology (WBE) is the area of study that is concerned with the 
analysis of WW to understand the incidence and distribution of factors relating to the health 
and welfare of the community. Wastewater-based drug epidemiology (WBDE) is specific to 
the distribution and incidence of drug use and the impact it poses to the welfare and health 
of the community. The theory behind WBDE is the understanding that when a drug is 
consumed, it is metabolised and broken down in the body and eventually eliminated in urine. 
It is the metabolites and biomarkers of the drug that are eliminated in urine that may be 
detected in WW21. From this, the drug concentration in WW can be determined and 
furthermore this can then be used to back-calculate the level of drug use in the 
community21,27. It has the benefit in that the methods involved in WBDE analysis are non-
invasive, with the potential to provide an estimate of societal drug use without implicating 
individuals within the community in the incriminating act, which has often been a deterrent 
when completing voluntary surveys directed to recent drug use. WBE has also been utilised 
to measure the use and misuse of pharmaceuticals, specifically to assess the impact of 
excreted chemicals in WW to the environment and aquatic life21. The data collected from 
these studies can be utilised to illustrate the level of drug use in society, for example, which 
drugs have the highest rate of abuse and highlight various trends that can occur throughout 
the week or leading up to and around large public events such as music festivals. WBE for 
societal drug use can be coupled with other studies to assess the impact of excreted illicit 
drugs to the environment21. Research has been put forward to assess the use of legal 
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pharmaceuticals, but lack in the understanding of the impact that illicit drug use has on the 
surrounding environment21,78,79. Unlike surveys, the information collected from WBDE can 
provide close to real-time information on societal drug use with preliminary findings available 
much faster than collating all the information gathered from surveys. Surveys generally have 
a high rate of non-response,20 which is overcome with WBDE. WW sample collection can 
combine the entire population that the treatment plant serves and provide an estimate of 
societal drug use. Surveys rely on adequately sampling a normally distributed population as 
it requires extrapolation to encompass and include the population that did not partake in the 
voluntary survey. By doing so, estimates can involve large error rates and significantly 
misrepresent the level of illicit drug use in the community, even more so where surveys obtain 
little response rate5,20,21. Information on illicit drug use also comes from the arrest and drug 
seizure reports from law enforcement. However, this information provides a significant bias 
in that virtually all the drug data is from illegal and incriminating acts21. Societal drug use can 
also be provided by healthcare and medical centres, like hospitals and general practices, but 
such information may be biased due to doctor-patient confidentiality21. Additionally, again, 
illicit drug users can be wary of approaching professionals in fear of incriminating themselves 
and being persecuted for the participation in an illegal act3. Over time there has been a 
decrease in the use of any one type of an illicit drug, but also saw an increase in the use of 
another, ecstasy or designer drugs4 (Table 1). 
 
Therefore, there is a need to have the ability to track trends in drug use. Using WBDE, trends 
and hotspots in illicit drug use can be identified and used as a means to devise and assess the 
impact of policies or strategies that can effectively target and combat the drug use epidemic. 
However, data collected from WBDE on societal drug use cannot be depended upon alone to 
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measure the success or non-success of drug policies and strategies, rather incorporated into 
a framework that can assess this80. Although WBDE studies are still in their infancy, majority 
of which have been conducted within the last decade, they have demonstrated a great 
potential in understanding and obtaining an objective and unbiased estimate of drug use in a 
community. 
9.1 THE FOUR PARAMETERS 
There are four typical parameters required for WBDE studies: 1) concentration of the drug 
residue target found in WW, 2) flow rate at the WWTP, 3) excretion factor of the drug residue 
target and 4) the number of people the treatment plant serves. Each of these factors requires 
accurate methods of acquiring their respective data. Zuccato et al. laid out the first initial 
studies relating to WBDE to estimate societal drug use by utilising the four factors mentioned 
previously to back-calculate the level of illicit drug use within a community27. The basic 
foundations of the study involved solid phase extraction (SPE) techniques to extract drug 
residue targets present in samples collected from influent WW, together with quantitation 
methods utilising LC-MS/MS to determine drug concentration. Secondly, flow rate data of 
Table 1. Prevalence of drug use within a population aged 14 and older from 1998 and 2004, 
and 2004 as a function of 1998 drug use rates2 
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WW through the treatment plant are often 
acquired directly from the treatment plant at 
which the sampling process is conducted. Thirdly, 
excretion factors of the drug residue targets are 
obtained from previous literature on the 
pharmacokinetics of the drug. And finally, the 
number of people that the WWTP serves is 
estimated from census surveys conducted by the 
government. Since the utilisation of WBE to 
estimate societal drug use, each of these factors 
has undergone refinement as technology advances and more studies are contributing to this 
new area of research.  
 
9.1.1 DRUG CONCENTRATION FROM DRUG ANALYTES  
The quantitation of DTRs with LC-MS/MS is an important step in the determination of societal 
drug use. It serves as one of the parameters in the back-calculation for the estimate of illicit 
drug use in the community. For this reason, there is a high importance placed on the selection 
of DTR, its collection from WW, storage and extraction, since they collectively, they impact 
the accuracy of this parameter. Linked to this parameter, is the knowledge of the selected 
DTRs’ excretory factors. Specifically, the fraction DTR is excreted from the parent drug. 
Additionally, results may often be presented as doses/day/1,000 people, which requires the 
knowledge of the typical dose of the drug, and subsequently the fraction of the dose that is 
excreted as the DTR. 
 
Figure 2. General overview of steps involved in 
wastewater-based drug epidemiology to estimate 
societal drug use37 
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9.1.1.1 SAMPLING COLLECTION, PREPARATION AND STORAGE 
The very first step in WBDE is the collection of WW sample. WW samples were generally 
collected as 24 hour composite samples of influent water. Sampling influent or effluent WW 
is dependent on the aim of the study. Utilising WBE to estimate societal drug use would be 
most beneficial from collecting influent WW samples, as sampling would occur before WW 
undergoes treatment, eliminating the risk of the DTR being removed before they are 
analytically detected through the study32. Collection of effluent water would better suit the 
aim to assess the effectiveness of WWTPs in removing illicit drug residues from the water, 
and furthermore the impact those residues have on the aquatic life and agriculture once they 
are pumped back into the environment81-83. Initially, samples were collected by an automatic 
sampling device and kept refrigerated at 4 °C on site during the 24-hour collection, before 
analytical samples were derived from the composite samples. A composite sample describes 
a whole sample composed of subsamples collected across a selected population and/or time-
frame at specific intervals with the intention of obtaining a representative collective sample. 
In this case, for WBDE studies, 24-hour composite samples are collected to represent the total 
drug levels of a population for the day the samples are collected. Automatic sampling devices 
were either time-proportional, which collected a certain volume of WW at the allocated time 
intervals, or volume- or flow- proportional which collected either collects a certain volume of 
WW at time intervals that is determined by the flow of WW or a variable volume of WW is 
collected at defined time intervals. A study conducted by Castiglioni et al. assessed the 
uncertainties that are involved in WBDE. A comprehensive questionnaire was developed in 
order to systematically assess the sampling methods of various WWTPs in the study84. They 
had concluded that a volume- or flow-proportional  automatic sampling device would 
minimise the relative standard deviation involved with sample collection, as long as it was 
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performed in conjunction with short sampling intervals84. Alternatively, polar organic 
chemical integrative sampler, POCIS, has been demonstrated in the recovery of some illicit 
drug analytes present in effluent water40. However, there are several limitations in its 
utilisation. Firstly, only drug residue targets that are polar in nature are collected by this 
specific sampler, and so there is a risk of some DTRs being missed by this device. This will 
result in results misrepresenting societal drug use. Samples are taken from the raw WW 
composite on site once the 24-hour composite sample has been collected. Best practice 
sampling methods were recommended and assessed for their ability to represent daily 
composite samples with minimal uncertainty by Castiglioni et al84. Briefly, the sampling 
protocol provided to the staff at the WWTP were as follows; a 400 mL subsample would be 
aliquoted from the 24 hour composite influent WW collection into a polypropylene bottle 
that has been pre-rinsed with Milli-Q water and methanol, the sample is then acidified on-
site at pH 2, using 2.5 mL of hydrochloric acid solution25,84. Acidification of the sample would 
reduce the likelihood of in-sample transformations of the drug residue targets85. The samples 
are stored at -20 °C in the dark until chemical analyses are conducted within 2 months. Some 
studies have opted for other methods of storage depending on the schedule of analytical 
testing, such as storage at 4 °C in the dark, if the sample is to be analysed within 3 days.  
 
9.1.1.2 SELECTION OF DRUG TARGET RESIDUES (DTR) 
At this point, WBDE for estimating societal drug use is only able to screen and evaluate known 
illicit drugs. This is because the excretion factors need to be known in order to be able to back-
calculate to obtain an estimate of societal drug use for that illicit drug. Alternatively, if a 
suitable DTR is identified, it may be utilised merely to detect the presence of that illicit drug. 
Studies are often conducted to select and identify suitable DTRs. DTRs identified tend to be 
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metabolites resulting from the internal metabolism of the parent drug so that estimated drug 
use from WBDE can accurately demonstrate drug abuse resulting from human use. Selecting 
an appropriate DTR is important to establish a foundation for the remainder of WBDE, 
especially for the back-calculation that estimates the level of illicit drug use of the community. 
The selected DTR must fulfil specific criteria. The DTR should be stable in WW26,85-89, a 
significant excretion product26, have sufficient data on their excretion factors26,29 and have a 
chemical profile that has a reasonable recovery rate from extraction methods90, in order to 
accurately extrapolate to estimate societal drug use.  
 
A study conducted by Castiglioni et al. evaluated cocaine and its metabolites as potential DTRs 
in WW,  by assessing each of their stabilities in WW as well as the recovery rate based on the 
gold standard methods of SPE followed by the analysis with (LC-MS/MS)90. In cases where the 
chemical profile of the potential DTR under assessment did not allow for a good recovery rate 
from SPE, steps can be taken to optimise the retention of the metabolite analyte during 
extraction methods. For example, ecgonine, a minor metabolite assessed as a potential DTR 
for cocaine, is highly polar and water-soluble resulting in a weak recovery rate from SPE using 
Oasis MCX cartridges (60 mg)90. More sorbent material (150 mg) was added to the cartridges 
in order to overcome this successfully increasing the retention of ECG on Oasis MCX 
cartridges34. Studies conducted in WBDE to estimate societal drug use have used the main 
major excretory metabolite as the DTR and often include in-study validation of the methods 
conducted. Although these tend to be the ideal DTR for these studies, limited studies have 
been dedicated to assessing their ability to directly portray illicit drug use of the parent drug. 
The pharmacology of drug action is very complex. The pharmacokinetics of the drug is 
influenced by many factors, as previously discussed, including drug-drug interactions (DDI). 
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These can lead to side effects and is often the reason why some medication cannot be taken 
in conjunction with another. A study conducted by Harris et al. described the variation in the 
pharmacology of cocaethylene, a metabolite of cocaine, following the concurrent 
consumption with alcohol. This was noted in a study conducted by van Nujis et al., and a 
correction factor was implemented in their study on WBDE focused on estimating cocaine use 
within Brussels, Belgium22. It has been demonstrated then, that drug excretion profiles are 
impacted by substances taken in conjunction to the drug, and therefore studies have the need 
to incorporate uncertainties regarding drug excretion profiles in combination with other 
common substances. 
 
9.1.1.3 SAMPLE EXTRACTION AND CHEMICAL ANALYSIS 
A vast number of studies have continuously utilised SPE to extract and isolate drug residue 
targets from the samples collected from WW22,24,26,27,36,44,46,89,91,92. Some studies have also 
opted for a direct injection method, which has been tested to reduce DTR degradation38,88,93. 
However, storage methods that have been mentioned above, also have been utilised as a way 
to reduce degradation of DTR in samples before analysis can be performed. Wastewater 
based epidemiology to estimate societal drug use often underestimates the level of drug use 
within a community. It has been suggested that this is partly due to the disregard of the 
sorption of DTR) into suspended particulate matter (SPM) which is usually filtered from the 
sample32,94,95. To overcome this, an additional extraction method, pressurised liquid 
extraction (PLE), have been incorporated into WBDE. However, there is also conflicting 
evidence that the absorption of illicit drug analytes into SPM, which is filtered prior to SPE 




Samples are spiked with internal standards to serve as quality control and assess instrument 
performance and the precision of the quantitative analysis. Overwhelmingly, LC-MS/MS has 
remained the gold standard to identify and quantify the levels of DTRs in samples. Specifically, 
high-performance liquid chromatography (HPLC) coupled to a triple quadruple (QqQ) mass 
spectrometer equipped with electrospray ionisation (ESI) interface. Electrospray ionisation is 
the technique of choice to produce ions for LC-MS/MS. Multiple reaction monitoring (MRM) 
mode was often favoured to perform the quantitative analyses, as it has the capability to 
assess multiple product ions from one or more precursor ions. LC-MS/MS is highly recognised 
and accepted within the field of WBDE, but an ongoing limitation with this method is that LC-
MS/MS is only capable of quantifying and analysing targeted drug residues for which this 
technique has been developed for. Those that are not actively screened for, tend to be 
omitted and ignored from studies. To overcome this, high-resolution MS can be incorporated 
as it demonstrates the potential to screen for non-targeted drug residues41,96-98. A recent 
Australian study has also evaluated the use of a data-independent acquisition (DIA) method 
of Sequential Window Acquisition of all THeoretical fragment-ion spectra, most commonly 
referred to as SWATH, concurrent to liquid chromatography-quadruple time of flight 
instrument to qualitatively screen for compounds in WW39. Utilising a continuously updated 
database, SWATH was able to identify and confirm the presence of 100 compounds within 
WW, with 61 compounds confirmed to be present within all samples collected across the 14-
month period39. This study was able to identify the use of two new psychoactive substances 
in South Australian WW, subsequently quantified by high-performance liquid 
chromatography coupled with a triple, quadruple mass spectrometer instrument equipped 
with electrospray ionisation (ESI) interface39. Although these techniques will not be able to 
evaluate the presence of illicit drug targets in WW quantitatively, it is a significant advance 
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for WBDE, specifically for the screening of new psychoactive substances that are continually 
developed and have an extensive contribution to the illegal drug market. Furthermore, the 
study conducted by Bade et al., demonstrated the value of combining qualitative analysis 
through high-resolution MS and SWATH with subsequent quantitative analyses in WBDE39. 
 
9.1.2 FLOW RATE  
Another critical factor is the flow rate of WW through the treatment plant. This factor is 
variable day-to-day and can be affected by the precipitation in the area. Heavy precipitation 
would result in a dilution of the presence of DTRs in the collected sample. Therefore, it is 
essential to obtain flow rate from the treatment plant respective for the 24-hour composite 
sample. As this is an important factor, the majority of the studies conducted in the area of 
WBDE have taken note that their study has been conducted during the dry season with no 
precipitation in order to remove the uncertainty that comes with the added variation of 
precipitation32,89. Flow rate data are often obtained from the WWTP where the study is 
conducted rather than independently measured. This is because it would reduce costs since 
this data are something that the treatment plant readily and consistently measured as part of 
protocol. To date, there has been limited study focused on refining flow rate estimates. An 
accepted method of obtaining flow rate from WWTPs is the application of a specially tailored 
questionnaire that inquires on the standard WWTP protocols on flow rate measurements, 
and the active cooperation between WWTP personnel and WBDE investigators. 
 
9.1.3 EXCRETION RATE  
The excretion rate of the selected drug analyte is the proportion of the parent drug that is 
converted to the DTR. This is determined by the pharmacokinetics and pharmacodynamics of 
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the drug55,56,60. The large proportion of the available information on drug analyte excretion 
data come from studies conducted in the 1980s, or they tend to have a minimal number of 
subjects29. Based on this, the knowledge of drug-specific pharmacology is quite limited and 
requires to be updated in order to be effectively utilised in WBDE. Each study in WBDE has 
also only based their drug excretion data on one set of results, and this is where a meta-
analysis of the excretion rate and other pharmacokinetic data from many studies would be 
useful and provide a more accurate population-derived understanding of these parameters.  
It has also been discussed that the individuals’ genetics also play a part in the pharmacology 
of the drug and can be studied through pharmacoepidemiology. However, to conduct studies 
in drug pharmacology is costly and quite difficult to measure and assess all the parameters 
involved in the drug’s pharmacology. Additionally, there are ethical considerations when it 
comes to the study of illicit drug pharmacology on subjects. The added hurdle occurs when it 
comes to studying pharmacoepidemiology, which would require many subjects to 
demonstrate and represent the population drug pharmacology adequately. Studies 
conducted for WBDE utilises excretion rate data based on one drug pharmacology study. 
Therefore, there is a need for a comprehensive meta-analysis on the pharmacokinetics of the 
drug, specifically the excretory profiles of illicit drugs and their metabolites that may be 
DTRs26,32,99. These studies would provide data on the excretion values for various illicit drugs 
as a mean value but additionally indicate the variation and uncertainty that will occur within 
a population as per pharmacoepidemiologic studies. Furthermore, as Baker et al. have 





The excretion rate of the drug analyte is a crucial factor for the back-calculation in WBDE, 
where slight differences in the data would result in magnitudes of error. A considerable 
emphasis should be put on studies conducted in this area in order to improve the accuracy of 
WBDE in estimating societal illicit drug use29. 
 
9.1.4 POPULATION ESTIMATION  
The premise of WBDE relies on the accurate estimation of the number of people the targeted 
treatment plant serves. The first studies conducted in WBDE utilised census surveys to obtain 
the number of individuals in the selected community. There are various flaws with the 
acquired data as this would also take into account infants and young children who evidently 
would not be exposed to the use of illicit drugs. Census data also only takes into account those 
living in homes and not those that are homeless. This is significant, as a recent document 
published by the Australian Institute for Health and Welfare, assessing the impact of alcohol, 
and illicit drug use on the burden of disease, have found that those in lower-income situations 
are more likely to participate in the act of illicit drug abuse6. For this reason, estimations on 
societal illicit drug use have always been underestimated24,27. Due to the high variability in a 
population that can occur day-to-day; as a result of commuting, holiday periods, et 
cetera22,100,101; population estimates cannot be established merely by static census survey 
results. Therefore, there has been a need to identify another method to estimate the number 
of contributing persons within the WW catchment, but also assess the fluctuations in 
population. This concept follows the understanding that there are chemical analytes that are 
excreted by the human body that may be quantified alongside drug analytes in WBDE as 
population biomarkers to estimate population numbers. A number of population biomarkers 
have been proposed. Firstly, water quality parameters, biological oxygen demand, chemical 
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oxygen demand, phosphorus and nitrogen that are routinely measured by treatment plant 
personnel, has been utilised the most in studies to indicate population22,23,29,45. However, they 
have not been validated in their ability to estimate population size. The source of these 
compounds are not human-specific and can be contributed to WW by industrial means, thus 
resulting in very large population estimates22. A number of endogenous substances such as 
creatinine, cortisol, cholesterol, cotinine and 5-hydroxyindoleacetic acid (5-HIAA), were 
proposed as potential population biomarkers. These, among others, were assesseded in  a 
study conducted by Chen et al. as potential population biomarkers by evaluating their stability 
and prevalence consistency in WW, quantification methods, as well as the correlation 
between excretion and census population101. In their studies, only cotinine and 5-HIAA were 
identified as suitable population biomarkers, however cotinine is a metabolite resulting from 
the metabolism of tobacco101. Therefore, this biomarker is vulnerable to variations based on 
the culture of smoking habits within the community. Whereas, 5-HIAA is a metabolite of 
serotonin, an endogenous substance found in all humans, making it a more suitable 
population biomarker which can also be utilised for universal comparisons. Recently, 
ammonium has also been proposed as a possible population biomarker102, as it is an indirect 
marker of urine. Population biomarkers have the potential to provide an indication to the 
number of individuals within the WW catchment, can be analysed alongside the DTRs, and 
like WBDE, evaluate the fluctuations in a population that can occur day-to-day, adding to the 
accuracy of drug use estimates. The limitation that remains still is that population estimates 
continue to include young children, increasing the uncertainty of drug use estimates. 
However, this level of uncertainty may always be present in WBDE as there is no method to 
distinguish between children and adults based on excreted endogenous substances, apart 
from census data which takes extensive time to collect and assess. 
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9.2 VALIDITY OF METHODOLOGY 
In terms of validation of the methods involved in WBDE, there have not been many studies 
dedicated towards this area23,29,42. Most studies do, however, conduct in-study validation of 
their methods to ensure the quality of data collected29,32,44,89,103 .  
 
These studies do so by incorporating isotopically labelled internal standards, specifically 
deuterated internal standards, to serve as quality controls and reference standards to 
produce calibration curves22,27,54,89,103. Briefly, a known volume of known incremental 
concentrations of the reference standard and a fixed volume and concentration of an internal 
standard is added to make up standard solutions. These standard solutions are analysed, and 
the ratio of the area generated by the peak of the reference standard to the internal standard 
is calculated. These points will then form a calibration curve from which unknown 
concentrations of drug target analytes can be derived. This is done by calculating the ratio 
between the area under the curve of the peak generated by the analyte to the internal 
standard. The incorporation of an internal standard is the most beneficial in methods where 
the volumetric loss of the sample is probable, in order to compensate for uncontrollable 
changes that occur within the instrument utilised for the analysis. In addition, many studies 
have also calculated the instrumental detection limits (IDL), instrumental quantification limits 
(IQL), limit of detection (LOD) and limit of quantification (LOQ) to ensure the that the data 
collected and reported are within the limits of reasonable reliability24,26,27,89.  
 
The stability of metabolites that are the target drug residues utilised in WBDE is an important 
aspect that continues to require assessment85,86. Several studies conduct metabolite stability 
assessments alongside their WBDE experiments to demonstrate that the subsequent WW 
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drug concentrations obtained are reliable by eliminating the variability of DTR 
degradation26,32,89. The stability of drug metabolites in WW exhibits variability depending on 
the contents and presentation of certain substances in its environment, and for this reason, 
concurrent metabolite stability studies prove to be advantageous for that single study. 
However, this does add a layer of analyses to the experiment that already exhibits many 
variables. By conducting drug metabolite stability in WW studies87,88, and renewing that 
knowledge continuously, the study may provide data that can be utilised by many WBDE 
studies and allow for a standard protocol to be put in place. This additionally may allow for 
the ease of comparison between communities, cities, states and countries.  
 
10. CONCLUSION 
WBDE is an emerging area to study illicit drug use in society. It has demonstrated the potential 
to objectively evaluate and estimate societal drug use, providing near real-time data and 
identifying drug use trends within a time course, as well as identifying hot spots of drug use. 
Utilising WBDE to estimate societal drug use also has the benefit of  providing this information 
non-invasively, which avoids implicating any individual in illegal activity. It has also shown 
potential in detecting emerging illicit drugs, such as NPSs, by incorporating a secondary 
method utilising high-resolution MS as a screening method in conjunction with SWATH, data-
independent acquisition approach. The information garnered from these studies can assist 
police to focus their efforts to tackle drug abuse hotspots identified, assist policy makers to 
develop strategies to deter society in participating in illicit drug use. However, WBDE remains 
a relatively new area of study and requires further study to refine its methods to obtain 
further accurate estimates of societal drug use. This literature review has identified some 
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limitations and areas of WBDE that require more studies dedicated to combat these 
limitations. 
 
There are four factors that influence the calculation of societal drug use. These include drug 
concentration in WW, flow rate of WW through the treatment plant, the excretion factor of 
the DTR and the number of people contributing to the WW catchment. Each of these factors 
plays an important role in understanding and calculating societal drug use, and therefore it is 
crucial to obtain accurate data for each component. The limitations regarding in obtaining the 
drug concentrations in WW lie with the processes pertaining to the sampling, storage, 
extraction and chemical analyses of the samples.  
 
Studies often report that the results obtained from WBDE are underestimations of actual 
societal drug use. Poor sorption of drug target analytes during SPE methods will limit what 
quantitative analyses are able to detect and quantify. A validation study conducted by van 
Nujis et al. assessed two sorption polymers, Oasis HLB and Oasis MCX, which found that 
extraction efficiencies and recoveries were generally reproducible for both sorbents, but also 
found that its effectiveness relied on the chemical profile of the drug target analytes104. 
Further analysis determined that Oasis HLB would be the more favourable given its suitability 
to acidic, basic and neutral analytes.  
 
Underestimation of drug concentration in WW can also be attributed to the exclusion of DTRs 
sorption into SPM which are often filtered out and discarded as a step carried out for 
SPE32,94,95. A study undertaken by Baker et al. assessed and validated the significance of DTR 
sorption in SPM by carrying out PLE on WW samples and subsequently analysed using LC-
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MS/MS94. The underestimation of drug concentration in water can be due to the unknown 
processes that occur to the DTR whilst in WW, such as interaction with bacteria and other 
substances present, and therefore some studies should be directed towards furthering the 
understanding of the processes that DTR may undergo whilst in WW.  
 
Flow rate data is often obtained through communication and cooperation between WBDE 
investigators and the WWTP personnel, as this is data readily collected as part of protocol at 
the treatment plant. At this point, this has been the best practice protocol adopted by 
investigators41,47. In order to minimise error that comes from the massive influx of influent 
water that can come from precipitation, most studies are conducted in the dry season and is 
noted as such or otherwise32,45,89,100,104.  
 
The information on excretion factor of DTRs, mostly metabolites of drugs, has been obtained 
from studies with limited scope, some conducted in the 1980s and with a limited number of 
subjects29. For this reason, excretion data should be updated and a meta-analysis should be 
conducted on the available data, rather than basing WBDE on solitary pharmacokinetic 
studies. These studies should also be undertaken with a pharmacoepidemiology aspect, 
additionally assessing the differences in excretion rate as a function of the route of 
administration29,32,99. However, the likelihood of being able to conduct longitudinal 
epidemiology studies on the pharmacokinetics of an enormous range of drugs, as well as 
drugs that are continuously being discovered, is highly unlikely due to the considerable costs 




The final major parameter contributing to WW analysis is the estimation of population that 
the WWTP serves. Initially this data was obtained from the design capacity of the WWTP or 
from census surveys25-27. However this was demonstrated to be inaccurate to utilise static 
figure as fluctuations in population can occur day-to-day. Studies have been conducted 
towards identifying possible population biomarkers to estimate population data for 
WBDE45,93,102,106,107. These studies identifying and evaluating population biomarkers, 
specifically in relation to WBDE, are all relatively recent. Possible biomarkers that have been 
proposed include human-specific compounds106, ammonium102, pharmaceuticals and 
personal care products45,93 and genetic biomarkers107. Each of these proposed biomarkers has 
demonstrated an ability to provide information regarding the number of people served by 
the catchment. However, a common limitation identified throughout that is significant to 
WBDE, is the inability to separate the population based on potential drug users based on age 
groups24 and remove individuals that would not be expected to partake in drug use, eg. 
children.  
 
It is important to realise that for some of these parameters, ideal conditions cannot be met 
and therefore the only thing that can be achieved is to continuously refine the methods of 
WBDE in order to objectively and accurately estimate societal drug use. Another limitation of 
WBDE is the inability to differentiate between individuals based on the level of use, whether 
they are dependent users or recreational; or whether they are mono- or poly-drug users. Each 
individual drug use also displays variation in their dosage preference, and so WBDE cannot 
determine whether estimated drug use is the result of a significant portion of the community 
engage in casual drug use or whether a small group of illicit drug users are chronic users. 
Additionally, because drug doses can vary highly between individual, it is difficult to express 
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results in relation to dose per individual, for example, “dose/day/1,000 persons”. Estimated 
drug use obtained by WBDE is not stand-alone and can be utilised complementary with other 
studies, for example, incorporating the findings to a framework to assess the performance of 
law enforcement80, and therefore as an extension, the performance of policy-makers and the 
strategies proposed to deter illicit drug use. WBDE has also demonstrated the potential to 
detect traces of doping by athletes, which will contribute to the sporting field50. 
 
This literature review on the current knowledge of WDBE to estimate societal drug use has 
demonstrated the capacity and potential of these studies to objectively and directly assess 
DTRs in WW. This field of study remains in its infancy and continuously requires the addition 
of new and current knowledge of drug metabolites and its stability in WW; as well as further 
refinement in the methodology of sample extraction and analysis, flow rate determination, 
pharmacoepidemiology studies on the pharmacokinetics of drugs and the identification of an 
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Wastewater-based Drug Epidemiology to 





Illicit drug use has many consequences resulting in social, health and economic harm. In order 
to adequately inform the community and law enforcement to efficiently direct their efforts, 
an objective method of quantifying societal drug use would be useful. To this end, efforts to 
ascertain societal drug use have relied upon community surveys and extrapolation from law 
enforcement seizures, which often present the data as biased or skewed due to a small 
sample size and other associated limitations. 
In recent times, wastewater-based drug epidemiology (WBDE) has been proposed as 
a suitable means to objectively quantify societal drug use.  It is a method contingent upon the 
concept of measuring drug metabolites or biomarkers in wastewater (WW), from which levels 
of societal drug use are estimated and quantified through extrapolation. The typical methods 
involve the collection of influent WW from treatment plants where samples are aliquoted and 
extracted using solid phase extraction (SPE) techniques. The extracted samples are then 
quantified to obtain drug concentration using liquid chromatography coupled with tandem 
mass spectrometry (LC-MS/MS). Together with drug concentration, flow rate, drug excretion 
rate and WW catchment population, an estimate of societal drug use can be obtained through 
back-calculations. Each of these parameters hold a significant weight in WBDE and require 
accurate methods in obtaining each parameter.  
The aim of this study was to therefore, critically review the various methods of WBDE 
that have been applied in Australia and in Europe. The outcomes of the assessment pertaining 
to their validity in directly and objectively measuring societal drug use will be presented. 
Keywords: wastewater-based drug epidemiology, wastewater-based epidemiology, illicit 
drugs, drug abuse, estimate, societal drug use, population 
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Illicit drug use has become a worldwide epidemic resulting in consequences that have a 
burden on every facet that makes up a community. It places a burden on the social, medical, 
policing and economic branches of society. In the period 2004/05, the tangible costs to the 
economy totalled to just over 6.9 billion dollars, as a result of a reduction in the workforce, 
absenteeism, premature deaths and illnesses, use of pharmaceuticals, to name a few1. Of 
course, not all burdens can be expressed as a monetary loss, illicit drug use can result in the 
years of life lost (YLL) and the years lived with disability (YLD)1-3. The Australian Institute of 
Health and Welfare reported that in 2011, illicit drug use resulted in 70,419 years of life lost, 
equivalent to 3.1% of all fatal burdens and 31,447 years lived with disability, equivalent to 
1.4% of all non-fatal burdens3. Illicit drug use has been shown to affect the individual’s 
interaction with society, resulting in a detrimental disconnection to the world around them. 
Although illicit drug use has been shown to be stabile across the recent years with the 
National Drug Strategy Household Survey of 2016 reporting a similar proportion of lifetime 
use to that reported in 2013, 43% and 42% respectively. However, the NDSHS also note that 
illicit drug use has gradually increased since 2001, at which point 38% of the Australian 
population aged 14 or older had used illicit drugs at some point of their life4. Between 1998/99 
and 2004/05, there has been an 11.3% increase in total cost of illicit drug use, when assessed 
using 2004/5 prices1. It is important to understand that the culture of illicit drug use has 
drastically changed across the space of decades, with the decline in the prevalence of some 
illicit drugs and the emergence of others, in particular, novel psychoactive substances (NPS). 
NPSs are synthetic chemicals that are manufactured to mimic the effects of existing 
psychoactive drugs, such as cannabinoids and ecstasy. The manufacture of NPSs occurs 
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rapidly and is easily achieved as it involves a minor adjustment to the chemical structure, 
often making it undetectable to many screening methods. It is for this reason that most NPSs 
avoid legislation. 
 
Understanding the true societal drug use is highly important. Accurately assessing real-time 
societal drug use will allow for the effective direction of the efforts of the various key 
community groups; law enforcement, medical professionals and government bodies such as 
policy makers. The negative ripple effect that illicit drug use produces starts with the 
individual and extending out to friends and family and then to the rest of the community. This 
has led to the prohibition of many drugs. By accurately estimating the level, relative 
proportion and prevalence of various illicit drug use, it could help bring a greater awareness 
to the drug epidemic. This understanding of societal drug use can be used in conjunction with 
policy frameworks to assess the success of these policies that have been put in place to 
combat the drug use epidemic5. Additionally, understanding the current trends and 
prevalence of various drugs, can assist medical and rehabilitation services to effectively 
budget and regulate programs.  
 
Past methods of measuring societal drug use was dependent on community and government 
surveys4,6-10. Self-reporting surveys are often open to bias as they are reliant on the 
individual’s recollection of events pertaining to drug use. This problem is compounded if the 
individual is under the influence whilst taking part in the survey, as the physiological and 
psychological effects of drugs can impact an individual’s recollection11,12. Another factor that 
places additional uncertainty in surveys is that often individuals are reluctant to be completely 
honest with their participation in illicit drug use, in fear of being reprimanded for their actions, 
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since such actions are illegal13. Surveys have a recurring problem of returning unresponsive, 
with only 1% of a population of 29,083, completing the survey in a study conducted assessing 
the participation in voluntary surveys14. Additionally, conducting surveys, distributing and 
analysing them thereafter has been demonstrated to be costly15. Therefore, police and 
medical reports are also collected to measure societal drug use, but these also present a bias; 
police reports will evidently report on the illegal activities, whereas medical reports are often 
restricted due to doctor-patient confidentiality. In order to accurately assess the level of 
societal drug use, such data should be collected utilising methods that are able to present 
such data in an unbiased and objective manner. To this extent, WBDE has been proposed as 
a means to do so.  
 
2.1 WASTEWATER-BASED DRUG EPIDEMIOLOGY 
Wastewater-based epidemiology (WBE) is the study pertaining to the analysis of wastewater 
(WW) to understand the incidence and distribution of factors relating to the health and 
welfare of a community. Furthermore, wastewater-based drug epidemiology (WBDE) is the 
study pertaining to the analysis of WW to understand the incidence and distribution of drug 
use. The concept of WBDE is impingent on the understanding that consumed drugs are 
metabolised and eliminated from the body, and these eliminated factors are drug biomarkers 
or metabolites that are present in urine and therefore in WW. It is then possible to quantify 
this and obtain drug concentration in WW. Together with other important parameters; flow 
rate, drug excretion rate and WW catchment population; through back-calculation, an 
estimate on societal drug use can be obtained. It has the potential to provide close to real-
time estimate on societal drug use, assess trends and identify drug use hotspots. WBDE 
studies are non-invasive and protects the privacy of all individuals, collecting information 
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without incriminating any one individual, thus providing an unbiased understanding of 
societal drug use. The concept was first proposed by Daughton et al. with the aim to assess 
the effect of drug excretion products to bring awareness of societal illicit drug use to the 
community and its impact on the environment, for example, aquatic life13. Since then, studies 
have utilised WBDE as a means to assess and quantify the level of societal drug use. Zucatto 
et al. laid out the first initial studies contributing to WBDE and assessed cocaine use in Italy 
by back-calculating using four factors; drug concentration quantified in WW, flow rate of WW 
through the treatment plant, excretion rate of the drug target residues (DTR) and the number 
of people served by the WWTP catchment16. Since then, many studies have been conducted 
with the aim of optimising and refining these robust methods laid out by Zuccato et al. 
towards a method that provide greater accuracy on the understanding of societal drug use. 
WBDE studies are still in their infancy, with most of the studies having been conducted within 
the 15 years, but WBDE demonstrates a great potential to contribute to the knowledge of 
societal drug use.  
 
3. DISCUSSION 
WBDE is the study and analysis of WW to understand the incidence and distribution of drug 
use that affects societal health and welfare. The concept of WBDE is impingent on the 
understanding that the human consumption of illicit drugs undergoes metabolism within the 
body and is eliminated13. Biomarkers and metabolites of the illicit drug are eliminated from 
the human body and are present in urine and therefore expected to be present in WW13. It is 
these biomarkers and drug metabolites that are the DTRs for WBDE analysis. In WBDE, there 
are four parameters that are paramount to the back-calculations used to estimate societal 
drug use. These are, drug concentration derived from the quantitation of DTR (5.1), flow rate 
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of WW through the (WWTP) (5.2), drug excretion rates from the understanding of drug 
pharmacology (5.3) and population served by WWTP catchment (5.4). Each of these 
parameters play an important and crucial role in WBDE and therefore require optimised 
methods to accurately obtain the relevant data. These parameters have factors that influence 
the accuracy of the data obtained for them. This review aims to assess the methods involved 
in obtaining each parameter.  
 
3.1 DRUG CONCENTRATION 
Drug concentration is derived from the quantitation of DTRs within WW. Factors that affect 
the accuracy of drug concentration are the sampling, preparation and storage protocols 
(5.1.1), DTR selection (5.1.2) and sample extraction and chemical analysis (5.1.3). Each of 
these plays a crucial role in obtaining drug concentration. 
 
3.1.1 SAMPLE COLLECTION, PREPARATION AND STORAGE 
This is the very first step in WBDE and sets the foundation for the remainder of the study. In 
order to obtain a representative sample of the day, a 24-hour composite sample is obtained 
of influent water utilising a flow- or volume-proportional automatic sampling device with 
short sampling intervals. The decision to choose influent WW samples over effluent WW 
samples is often in relation to bypassing the risk of DTRs being filtered or removed by the 
WWTP before it can be quantified17. Collecting influent WW samples can be useful in cases 
assessing the effectiveness of WWTP in removing illicit drug residues from WW or assessing 
the effects of remnant illicit drug residues on the environment13. A study conducted by 
Castiglioni et al. assessed the uncertainties involved with WBDE and with respect to sampling 
devices, they had concluded that in order to avoid bias and minimise the relative standard 
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deviation involved with sample collection, a flow- or volume-proportional automatic sampling 
device with short intervals would be the most effective. An alternative sampling device had 
been proposed, a polar organic chemical integrative sampler (POCIS) which was 
demonstrated to recover some illicit drug analytes present in effluent water18 but also 
exhibited the limitation in that only polar drug analytes are detected by this device. This would 
result in the misrepresentation of the results to estimate societal drug use. This device may 
be useful if a specific drug is the subject of a WBDE and has a polar DTR that can be detected 
by POCIS. Once 24-hour composite samples have been collected, analytical subsamples are 
derived from the original composite sample. These analytical subsamples are acidified to 
reduce the risk of in-sample transformations19 and kept refrigerated in the dark at 4 °C if the 
sample will be analysed within 3 days16,20,21, or at -20 °C if samples are analysed within 2 
months of collection16,22-24. 
 
3.1.2 SELECTION OF DRUG TARGET ANALYTES 
WBDE is based on the understanding that drugs that are consumed will undergo metabolism 
within the human body and eliminated as biomarkers of the drug or its metabolites, with a 
small fraction possibly remaining as the parent drug. Each of these possible drug analytes 
have different pharmacological profiles and therefore behave differently. It is important to 
select an appropriate one in order to accurately estimate societal drug use. Several criteria 
must be met in order to be selected as an appropriate DTR for the illicit drug in question. The 
DTR must be stable in WW19,23,25-28, must be a significant excretion product25, have sufficient 
pharmacological excretion data25,29 and have a chemical profile that has a reasonable 
recovery rate30. A study conducted by Castiglioni et al. assessed cocaine and its metabolites 
as potential DTR for WBDE and found that major cocaine metabolite, benzoylecgonine (BZE) 
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was the best suited DTR for WBDE based on its occurrence and stability in WW30. This study 
also noted differences in stability assessments of DTR between studies23,30 where the 
experimental conditions were the same, and the only difference was the WW samples. This 
suggests that the nature and composition of WW highly influences the results that can be 
obtained from samples. To that end, DTR stability should be assessed within each study as a 
means to ensure the results that will be obtained from the study are reliable.  
 
3.1.3 SAMPLE EXTRACTION AND CHEMICAL ANALYSIS 
The most common extraction and subsequent quantitation methods that has become the 
mainstay of WBDE is SPE techniques and quantitation by means LC-MS/MS16,23,25,29,31-35. Most 
of these studies utilised high-performance liquid chromatography (HPLC) coupled to a triple 
quadruple (QqQ) mass spectrometer equipped with electrospray (ESI)16,35-37. Variations in the 
LC-MS/MS apparatus used; for example, high-performance or ultrahigh-performance LC, or 
triple quadruple or QTrap mass spectrometer, etc; has not been thoroughly evaluated and at 
this stage is not thought to result in a significant variation but is something that should be 
looked at in future studies. 
 
Some studies have identified limitations of WBDE that require additional methods to obtain 
a representation and estimate of whole societal drug use. A limitation that has been identified 
is the omission of suspended particulate matter (SPM) and the possibility of the sorption of 
DTR in SPM17,38,39, as it is often filtered from the samples before extraction techniques are 
performed20. This lead to the incorporation of pressurised liquid extraction (PLE) techniques 
to overcome this hurdle38. There is also conflicting evidence that the omission of the sorption 
of DTR in particulates for calculations does not impact the estimate enough to justify an extra 
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method to isolate SPM13,32. A continuous limitation that has been identified with the 
utilisation of LC-MS/MS techniques is that this method only allows for the quantitation of 
drug analytes that are actively under inquiry. Those that are not actively screened for are 
often missed. To overcome this, a qualitative method utilising high-resolution MS has been 
proposed to be incorporated into WDBE studies36,40-42. A recent study conducted in Australia 
employed both a qualitative and quantitative method, but also evaluated the use of a data-
independent acquisition method, Sequential Window Acquisition of all THeoretical fragment-
ion spectra (SWATH)35. SWATH is a data acquisition method that has a much narrower 
window of fragmentation, and therefore is able to separate fragment ions with greater 
discriminatory power. Utilised in conjunction with high-resolution MS, it allows for the 
qualitative screening and detection of all possible DTRs that are present in the sample. This 
method has primarily been used in the study of proteomics but has shown promising results 
in its utilisation for societal drug use estimate in WBDE, specifically in its ability to screen for 
NPS35. 
 
3.2 FLOW RATE 
The rate at which WW flows through the WWTP is an important factor that is required for the 
back-calculation in WBDE. This factor can vary day-to-day and is influenced by environmental 
factors, specifically precipitation, which is why majority of WBDE studies aim to be conducted 
during the dry weather season where the chance of precipitation to circumvent this added 
variability17,23. Flow rate data is often obtained from the WWTP as flow rate is routinely 
measured as part of the protocol. This would reduce costs for the study. It is therefore 
important to accurately obtain flow rate data from the WWTP and the accepted method to 
do so is through a specially tailored questionnaire, inquiring of the standard flow rate 
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measurement protocols of the WWTP, and the active and ongoing cooperation between the 
WWTP personnel and investigators43.  
 
3.3 EXCRETION RATE 
The underlying concept of WBDE is the understanding that drugs consumed by the human 
body are metabolised and broken down to their metabolites13. These metabolites are 
eventually eliminated from the body through urine. These metabolites and biomarkers are 
drug analytes targeted for WBDE studies13. The excretion rate of these selected DTRs 
describes the proportion of the parent drug that is converted to its metabolites or biomarkers. 
Excretion rate is a critical factor for WBDE, used in the back-calculation from the drug 
concentration detected in WW to an estimated total drug use load by the community. 
Excretion rate is a factor that is determined by the pharmacokinetics and pharmacodynamics 
of the drug44-46. The data derived from these studies exhibit many limitations such as being 
outdated, most having been conducted in the 1980s, or that they have minimal subjects29. 
WBDE studies have only based their pharmacologic excretion rates on a singular study, where 
rather, a meta-analysis of drug excretion rates would be more appropriate17,25,47. The 
knowledge of illicit drug-specific pharmacology is quite limited and requires not only an 
update and a larger sample size, but also an extension, specific to illicit drug use, is the 
exhibited variations in excretion rate as a result of various routes of administration29. A large 
sample size is important as a population may exhibit different drug pharmacological profiles 
to another. This concept is pharmacoepidemiology, which is the study of the incidence and 
distribution of pharmacological factors within a population. Advancing and conducting any 
pharmacological study requires many ethical considerations and are often difficult to set a 
control. Conducting these large-scale studies in order to hopefully accurately represent a 
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population requires a lot of monetary and time investment; however, it is emphasised that 
drug excretion rate, and drug pharmacology are extremely important factors to obtain 
accurate data in order to improve the accuracy of WBDE29. 
 
3.4 POPULATION ESTIMATE 
The premise of WBDE relies on the accurate estimation of the population that the WWTP 
serves. Initially, studies conducted in WBDE utilised census surveys to obtain the number of 
people within the selected community, or the estimated number of individuals within 
catchment from the WWTP. Various flaws follow this assumption, one being that the 
population estimation derived from both methods take into account infants and young 
children who would evidently be exempt from the use of illicit drugs. Secondly, census data 
would only take into account those living in homes and not those that are homeless. This is 
significant, as the socio-economic group most likely to partake in the actions of illicit drug use 
are those who are of a lower-income status3. And finally, these population estimates are 
static, but population numbers fluctuate day-to-day as a result of commuting, travelling due 
to holiday periods, et cetera48-50. Therefore, there have been studies aiming to identify a 
suitable population biomarker in WW to accurately estimate population. The concept is 
similar to that underpinning WBDE, an understanding that there is a chemical analyte 
excreted by the human body that may allow an accurate population estimate. Several 
population biomarkers have been proposed. Most common is the use of water quality 
parameters such as biological oxygen demand, chemical oxygen demand, phosphorus and 
nitrogen, routinely assessed by WWTP personnel29,33,50,51; however, these have not been 
validated in their ability to accurately estimate population size. Additionally, the source of 
these chemical analytes are not solely human, and can be derived from industrial processes33. 
60 
 
Endogenous substances48, ammonium52, an indirect biomarker for urine, and genetic 
biomarkers53 have been suggested as alternative population biomarkers. Each of these show 
promising results but have yet to be validated as accurate methods to estimate fluctuating 
population both short-term and long-term. Obtaining an accurate population is a difficult 
hurdle for WBDE, specifically to estimate societal illicit drug use in that population estimates 
through population biomarkers cannot distinguish from young children. Population 
fluctuations occur randomly and to varying degrees, and so may inherently present constant 
level of uncertainty. 
 
3.5 VALIDATION OF METHODS 
WBDE studies are still very much in their infancy, and so there have not been a large number 
dedicated solely to the validity of these studies in their accuracy to estimate societal drug 
use29,51,54. However, many studies conduct in-study validation of their methods to ensure the 
quality of the data that has been collected and analysed17,30,34,55. These studies incorporate 
isotopically labelled internal standards, specifically deuterated internal standards, to serve as 
quality controls and reference standards to produce calibration curves16,30,33,55,56. From this, 
the unknown concentrations of the DTRs can be derived. The incorporation of internal 
standards is quite suited WBDE, specifically as its methods involve techniques where 
volumetric loss of the sample is probable. It allows for the compensation of the uncontrollable 
changes that occur within the instrument utilised for the analysis. In addition, studies would 
also incorporate calculations to portray the uncertainties related to the instrument. These 
studies calculate the parameters, instrumental detection limits (IDL), instrumental 
quantification limits (IQL), limit of detection (LOD) and limit of quantification (LOQ) to ensure 
that the data obtained from the analysis are within the realms of reasonable 
61 
 
reliability16,22,23,25. There is a need for validation studies for WBDE as this area of study 
continues to evolve and requires method validity to ensure the reliability of these studies to 
objectively derive estimates of societal drug use.  
 
4. CONCLUSION 
WBDE is an emerging area of study that can assess the extent of drug use in society. It has 
demonstrated the ability to objectively evaluate and estimate societal drug use, providing 
close to real-time data, identifying trends and hotspots of drug use. WBDE is a non-invasive 
method and has the benefit of providing information on drug use without implicating any one 
individual in the illegal activity13, additionally demonstrated the potential to detect traces of 
doping by athletes in the sporting field57. Policy makers and law enforcement also have the 
ability to incorporate WBDE and its findings into a framework to assess the success of 
strategies that have been put in place to combat illicit drug use in the community5.  It has also 
shown the potential to detect and analyse drug analytes derived from NPSs35, a newer niche 
of illicit drugs available that often avoid legislation due to the minor structural changes of 
existing psychoactive substances. This is done by incorporating a qualitative method, utilising 
a high-resolution mass spectrometer equipped with SWATH, a data-independent acquisition 
method commonly used in proteomics, to screen for compounds that are not always initially 
targeted35. The information that is obtained from WBDE has the ability to assist police, health 
and medical facilities and government groups to effectively direct their efforts.  
 
So far, studies in WBDE have underestimated the level of societal drug use, indicating that 
either past methods of social drug use estimates through census surveys, police and medical 
records, have been overestimated, and/or methods of WBDE require refinement in order to 
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obtain reliable, objective and accurate estimates of societal drug use. Many studies have 
identified limitations to WBDE studies and areas of improvement required for the 
measurement of each parameter. A factor that has been identified contributing to 
underestimation of societal drug use, is the omission of DTR sorption into SPM, solid matter 
often filtered from the sample before extraction occurs20. To combat this, PLE techniques 
have been incorporated with the aim to encompass all forms of DTR found in WW29,30,58. 
Another level of uncertainty possibly contributing to the underestimation of social drug use, 
is the estimation of population served by the WWTP. The usage of static population numbers 
provided by census surveys or by WWTP catchment capacity, have shown to produce 
underestimates when utilised in back-calculations for WBDE16,25,59. For this case, population 
biomarkers that can be found in WW has been proposed as a method to measure 
population48,50,52,53. This approach has demonstrated potential when incorporated into 
WBDE, especially in short-term studies52. This is particularly advantageous over static 
population estimates as population is known to fluctuate, even day-to-day as a result of 
commuting, holiday periods, et cetera. Studies in population biomarkers are novel, requiring 
more study contributions and validation in its accuracy to accurately estimate population.  
 
The pharmacology aspect of WBDE is an area that exhibits a deficit in knowledge, 
requiring an update and refinement of excretion factors that are utilised for the back-
calculation of societal drug use. It has been suggested that a large-scale 
pharmacoepidemiology study and meta-analysis on illicit drugs is required, with a key to 
acknowledge the differences in excretion rate relative to the various routes of 
administration17,29,47. However, many studies have acknowledged that the ability to conduct 
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these longitudinal drug pharmacoepidemiology studies would be strenuous, consuming a 
large amount of money and resources60.  
 
It is important to acknowledge that some of these parameters, ideal conditions cannot be 
met and therefore WBDE can only move forward with continuous refinement of its methods 
to obtain as accurate and objective as possible estimates of societal drug use. A drawback of 
WBDE is that it cannot distinguish between recreational drug use and chronic and dependent 
drug use, or whether the individual uses various drugs or has a preferential use of one drug. 
Each individual drug user have their own preferences and their own dosage, making it difficult 
to estimate societal drug use based on drug dose.  
 
WBDE to estimate societal drug use has demonstrated a great potential to contribute to the 
understanding of illicit drug use within a community. The studies that have contributed to the 
current knowledge of WBDE have been conducted within the last decade and a half, 
establishing itself as an area still in its infancy. Future studies would require the advancement 
and refinement in each facet of WBDE, with a focus on drug pharmacoepidemiology studies, 
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